Catalent symptom agreement with AstraZeneca to expand COVID-19 AZD122 vaccine

Catalent, Inc. (NYSE: CTLT), the world’s leading provider of complex management technologies, drug production and progression solutions, biological products, mobile and genetic treatments and fitness products for customers, announced that Catalent Cell

Catalent will prepare the Harmans facility, near the Baltimore Washington International Airport (BWI), to allow multiple production trains to run in parallel to produce the vaccine candidate drug starting late in the third quarter of 2020. This agreement extends that of Catalents for the AZD1222 Program following the announcement in June that the Catalents plant in Anagni, Italy, will supply the full-scale filling and packaging of AZD1222 vials.

The adenovirus vector-based vaccine candidate, AZD1222, co-invented through the University of Oxford and its spin-off company, Vaccitech, and licensed through AstraZeneca. The candidate vaccine is currently in clinical trials.

“Catalent has great pleasure in producing viral vectors,” said Manja Boerman, Ph. D. , president of Catalent Cell

Catalents’ Harmans/BWI advertising production facility features single-use generation and houses more than 18,600 square meters of complex production of clinical and advertising gene treatments. an advertising scale and houses several CGMP production suites, adding filling/finishing, central centers and test labs, supply chain and garage capabilities. Catalent Biologics’ network also includes sterile pharmaceuticals and packaging services in Anagni, Italy, Brussels, Belgium and Bloomington Indiana, as well as other amenities in Europe and the United States for protein manufacturing, mobile treatments and biological research centers.

Notes for editors

About Catalent Cell

Catalenta cell

About Catalent

Catalent, Inc. (NYSE: CTLT) is the world’s leading provider of complex management technologies, progression and production responses for medicines, biological products, mobile and genetic treatments, and customer fitness products. With over 85 years of service to the industry, Catalent has a proven track record of bringing more ator-scale products to market faster, product functionality and ensuring a reliable global source of clinical and advertising products. Catalent employs more than 13,500 people, adding more than 2,400 scientists and technicians, to more than 40 facilities, and generated more than $2. 5 billion in annual revenue in fiscal 2019. Catalent is headquartered in Somerset, New Jersey. For more information, visit www. catalent. com

No products. Better treatments. Reliably provided. “¢

Forward-looking statement

The statements regarding the progression, good fortune, and management of clinical trials, launch skills, and long-term production contained in this release are forward-looking statements. They involve known and unknown dangers, uncertainties and other points that would possibly cause actual effects or functionality different from those expressed or implied in this version. Catalent has based its forward-looking statements on its existing expectations, assumptions, estimates and projections, which it believes are reasonable, but miscellaneous, points that add points beyond Catalents’ control, which could possibly have effects on long-term effects or functionality. Factors that could possibly have an effect on such forward-looking statements include: the rapidly evolving market for medicines and vaccines to deal with the COVID-19 pandemic, the existing or long-term effects of the COVID-19 pandemic, adding their effects on Catalents and their visitors. companies, the result of the progression of this or any competing vaccine or any remedy for COVID-19, the result of any review, inspection or other approvals through the United States Food and Drug Administration (FDA) or a similar fitness regulator, the visitor and payer acceptance of the proposed vaccine, any competing vaccine or remedy for COVID-19, competitor responses to an imaginable long-term release of this vaccine, adjustments in the economic climate general in regions where this product would possibly be marketed or among potential buyers of the product, adjustments to the fitnesscare reimbursement formula in regions where this product would possibly be marketed or elsewhere, competing projects in Catalent or AstraZen eca, relevant hazards with the chain source of the vaccine, exchange rate fluctuations that have an effect on Catalents’ ability to obtain ma mandatory fabrics for the production of the product, or any third party claim or dispute similar to mi vaccine. These and other vital points, adding those discussed in Risk Factors in Catalent, Inc. ‘s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 or in its Quarterly Report on Form 10- Q for the quarter ended. March 31, 2020 could potentially have long-term effects or functionality. Catalent makes the statements in this release only as of the date of this release, and Catalent disclaims any obligation, unless required by law, to update or revise any forward-looking statement, under any circumstances.

Citibank launches “Move Money to Citi” mobile banking offering a unique digital wealth management service

Philip Morris International appoints a new senior vice president of External Affairs to accelerate his journey into a smoke-free future

For a “private” transaction

YANTAI, China, September 30, 2020 / PRNewswire / – Newater Technology, Inc. (NASDAQ: NEWA) (“NEWA” or “Company”), developed in line with its service provider and manufacturer of membrane filtration products and similar engineering devices and systems used in wastewater processing, recycling and disposal, today announced that it has entered into a final agreement and merger plan (the “merger contract”) with Crouching Tiger Holding Limited , a limited liability-exempt undertaking incorporated under the laws of the Cayman Islands (“mother”) and Green Forest Holding Limited, a limited liability company incorporated under the laws of the British Virgin Islands and a subsidiary of four hundred according to the percentage of the parent company (“underwater merger”), according to which the parent company earns the corporate at a value of US$ 3. 65 consistent with non-unusual consisting of the percentage of the corporate.

Subject to the terms and situations of the Merger Agreement, on the effective date of the Merger (the “Effective Time”), Merger Sub will merge with and into the Company, and the Company will continue to be the Company surviving and becoming a wholly owned company. parent subsidiary (the “Merger”). At the Effective Moment, each of the Company’s non-unusual consistent percentages, with a nominal price of US $ 0. 001 consistent with the consistent percentage (the “Shares”), issued and noticeable without delay before the Effective TimeArray is canceled. in exchange for the right to obtain US $ 3. 65 consistent with a percentage consisting of money and without interest, for the Excluded Shares (the “Excluded Shares”), which come with (i) the percentages consisting of beneficial ownership through Mr. . Array Li Yuebiao (through its affiliate, Tigerwind Group Limited), Ms. Zhang Zhuo and Mr. Sui Xiangqian (through Forwater Holding Limited) (collectively, the “Renewable Shareholders”), (ii) Shares Held through holders of Shares that have been validly exercised and their valuation rights have not been withdrawn or lost in accordance with article 179 of the 2004 BVI Companies Act, as amended (the “Disside Shares “), and (iii) Shares (if any) held through the Company or any wholly owned subsidiary, ie, ct e or oblique of the Company. Each Excluded Share (other than Dissenting Shares) issued and noticeable without delay before the Effective Time, pursuant to the Merger and without any action through its holder, will be canceled and will cease to exist as of the Effective Time, and no attention will be given in this regard.

The parent intends to finance the merger with a mix of equity and money in the company. Mr. Li Yuebiao and Ms. Zhang Zhuo, through special cars owned through them (each a “Subscriber” and together, the “Subscribers”), have entered into percentage subscription agreements with the parent, by virtue of which the underwriters have agreed to acquire equity interests in the parent with money, the amount of which will be used through the parent to pay part of the aggregate care for the merger. The rest of the general attention of the merger will be paid with the money of the company shown on the balance sheet at closing. The parent company (i) has the right to seek choice financing to update the company’s use of such money prior to closing, and (ii) is obligated to make all moderate efforts to discharge choice financing from choice sources . for any shortfall in case the Company has enough money to be used as care for the merger. Both Mr. Li Yuebiao and Ms. Zhang Zhuo have entered into a limited guarantee in favor of the Company regarding the secure payment obligations of the parent company under the merger agreement.

The Company’s Board of Directors, acting with the unanimous board of the independent committee (the “independent committee”) formed through the Board of Directors, approved the merger agreement and proposed transactions, adding the merger, and to propose that the company’s shareholders vote to authorize and approve the merger contract and proposed transactions, adding the merger The independent committee , which is composed only of independent and selfless corporate administrators who are not affiliated with any of the parent companies, subcontractors of the merger, Mr. Li Yuebiao, Ms. Zhang Zhuo or one of the company’s managers, negotiated the terms of the merger agreement with the assistance of its monetary and legal advisers.

The merger, which is expected to close recently at the time of the 2021 quarter, is subject to standard final conditions, adding approval through affirmative voting by shareholders who provide more than fifty% (50%) of the Company’s notable shares, provide and vote user or by proxy as a single elegance in general meeting of shareholders of the Company duly convened for the approval of the merger contract and weighted operations through the merger, adding the merger. At the date of the merger contract, mobile shareholders agreed, under a voting agreement, to vote in favor of the merger agreement and the final touch of the proposed transactions, adding the merger. If completed, the merger will result in the corporation adjusting to a customary corporation and its non-unusual shares will no longer be indexed in the NASDAQ capital market.

Worthless

Additional transaction information

The Company will provide the Securities and Exchange Commission (the “SEC”) with a Report on Form 6-K related to the proposed transactions described in this announcement, which will come with the merger agreement. All parties are looking for the main points of the proposed merger. are invited to review those documents, which will be available on the SEC’s online page (http://www. sec. gov).

In connection with the proposed merger, the Company will prepare and mail a power circular to its shareholders. In addition, the safe participants in the proposed merger will prepare and mail to the Company’s shareholders a Transaction Register of Annex 13E-3. These documents will be archived or provided to the SEC. INVESTORS AND SHAREHOLDERS ARE REQUESTED TO READ THESE DOCUMENTS AND OTHER DOCUMENTS SECURED OR FURNISHED IN FULL WHEN AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS. In addition to receiving the Power Circular and Transaction Declaration in Annex 13E-3 by mail, shareholders must also download those documents, as well as other documents containing data on the Company, the proposed merger. and similar matters, free of charge, from the SEC website (http://www. sec. gov) or the SEC Public Reference Room on One Hundred F Street, NE, Room 1580, Washington, DC 20549 In addition, those documents may be downloaded, free of charge, by contacting the Company on the following phone and/or phone:

No donations or requests

The data contained in this communication are for data purposes only and do not constitute an offer to purchase a being offered to purchase, or a request for an offer to sell, subscribe to or acquire securities or the request for any vote or approval in a jurisdiction. under or in connection with proposed transactions or in a different manner, or any sale, issuance or movement of securities in a jurisdiction in violation of applicable law. No securities offer may be offered unless it is through a set of prospects. section 10 of the Securities Act of 1933, as amended, and in a different manner in accordance with applicable law.

About Newater Technology, Inc.

Founded in 2012 and founded in Yantai, China, the company, operating through its wholly owned subsidiary Yantai Jinzheng Eco-Technology Co. Ltd. , specializes in the development, manufacture and sale of DTRO (reverse disc tube osmosis) and DTNF (Newater Nanofiltration Disc Tube Membranes for the treatment, recycling and disposal of wastewater supplies incorporated technical responses into the technique and installation. Technical recommendation of water purification arrangements and services, and other project-related responses to transform wastewater into valuable blank water. about the company, scale in www. dtNEWA. com.

The core of the company includes:

For more information about the company, see: www. dtNEWA. com

Safe harbor

This press release forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s existing expectations and observations and involve known and unknown risks, uncertainties or other points the Company’s control, which would possibly result in actual corporate results , functionality or achievements, particularly other than the results, functionality or other expectations implied in such forward-looking statements. These points are indexed from time to time in our presentations with the Commission Stock Exchange, including but not fewer our Annual Report on Form 20-F for the era ended December 31, 2019 and our next reports on Form 6-K. Unless required by law, we have no obligation, and expressly waive any obligation, to update or amend any forward-looking statements, whether as a result of new information, long-term occasions or otherwise.

Leave a Comment Cancel Reply